RNA heart drug spinout to launch with $40M

Lexeo Therapeutics is launching a spinout focused on RNA-based therapies for genetic heart conditions, supported by up to $40 million from Perceptive Xontogeny Venture Funds and venBio Partners.

Why it matters: This move targets a critical unmet need in cardiology by advancing non-viral RNA therapies, potentially expanding access and treatment options for patients with inherited heart diseases.

Backstory: Lexeo is developing therapies for conditions like Friedreich’s ataxia and plakophilin-2 arrhythmia.

• Interim trial data for LX2006 showed promise in reducing cardiac complications tied to Friedreich’s ataxia.

Yes, but: The company has faced recent financial hurdles, including a trimmed IPO and workforce cuts.

Big picture: RNA therapeutics are emerging as a frontier in genetic medicine. By focusing on non-viral delivery, this new biotech aims to sidestep some of the safety and manufacturing challenges tied to viral vectors, broadening the platform’s potential reach.

Behind the money: Perceptive and venBio have deep experience backing early-stage biotech, previously investing heavily in neuroscience and precision medicine ventures.

• Lexeo retains a double-digit equity stake and could earn royalties and milestone payments.